Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Heat and pH-sensitive nanoparticles target tumors

Using a novel polymer that becomes unstable under the pH conditions inside tumor cells, investigators at Singapore's Institute of Bioengineering and Nanotechnology have developed a core-shell nanoparticle targeted to deliver drugs to tumors.

5 Feb 2007

Self-assembling nanoparticle releases drug into cell cytoplasm

A growing body of research leaves no doubt that nanoparticles can transport drugs into cancer cells, but what is less clear is that the drug payload can exit the tiny endosomes that pull nanoparticles into cells.

30 Oct 2006

Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer

Efforts to treat cancer using genes and other oligonucleotides, such as short interfering RNA (siRNA), that turn off the biochemical processes that trigger malignancies have been hindered by difficulties in delivering nucleic acids to tumors.

16 Oct 2006

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.

5 Oct 2006

Key parameters for encapsulating drugs in nanoparticles

One of the early, successful uses of nanoparticles has been to develop delivery vehicles capable of ferrying large amounts of water-insoluble drugs to tumors.

2 Oct 2006

Txr1 gene that affects human cancer cells' sensitivity to chemotherapy

Gene that affects human cancer cells' sensitivity to chemotherapy - an important finding in the effort to increase the effectiveness of chemotherapy.

6 Aug 2006

Trial of Topotecan following Carboplatin and Paclitaxel in treatment of ovarian cancer

The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended for future use.

2 Aug 2006

Buckyballs deliver multiple drugs simultaneously to tumors

Combining a monoclonal antibody known to target melanoma tumors with multiple C60 buckyballs, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have developed a new way to deliver multiple drugs simultaneously to tumors.

3 Jul 2006

Injection may prevent infertility in men receiving cancer chemotherapy

It may be possible to protect the testes of cancer patients against the loss of fertility caused by chemotherapy.

20 Jun 2006

Gleevec strangles drug-resistant, metastatic prostate cancer

A medication used to treat other types of cancer strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply, researchers from The University of Texas M. D. Anderson Cancer Center report in the June 7 issue of the Journal of the National Cancer Institute.

7 Jun 2006

HERA trial continues to demonstrate significant patient benefits from Herceptin

New 23-month follow-up data from HERA, one of the largest breast cancer trials ever carried out, show that Herceptin (trastuzumab) following standard chemotherapy significantly reduced the risk of death by 34% for women with early-stage HER2-positive breast cancer.

5 Jun 2006

Advancing nanoparticle-based imaging and therapy of brain cancer

Brain cancer is one of the most difficult malignancies to detect and treat, in large part because of the difficulty in getting imaging and therapeutic agents past the so-called blood-brain barrier and into the brain.

9 May 2006

Benefit of chemotherapy in breast cancer depends on estrogen status of tumors

When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the Journal of the American Medical Association.

11 Apr 2006

Biodegradable drug containing nano-particles effective in killing human breast tumors

Research studies, based at the University of Pennsylvania, demonstrate that biodegradable nano-particles containing two potent cancer-fighting drugs are effective in killing human breast tumors.

11 Apr 2006

Researchers find environmentally friendly ways to produce more Taxol

As the effective cancer-treatment drug Taxol enters its next generation, Michigan State University announces discoveries which point to both environmentally friendly ways to produce more Taxol, and ultimately innovations to produce a more potent second-generation drug.

28 Mar 2006

Trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin.) in combination with paclitaxel (Taxol.) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone.

23 Mar 2006

Impact of a scientific presentation on community treatment patterns for primary breast cancer

The oral presentation of data from a single study at a national scientific conference can have an important impact on patient treatment, even before study publication or Food and Drug Administration (FDA) approval

15 Mar 2006

Stents that release the drug paclitaxel to treat stenosis more effective than radiation therapy

Insertion of stents that release the drug paclitaxel to treat stenosis within an implanted bare-metal stent in a coronary artery reduces the risk of subsequent re-narrowing within the stent, when compared with treatment using intra-coronary radiation

13 Mar 2006

Drug-eluting stents best treatment for managing coronary restenosis

In the first published trial of its kind, a multi-center clinical study has shown that drug-eluting stents outperform the current "gold standard" radiation treatment in managing coronary restenosis and in preventing further clogging of coronary arteries.

13 Mar 2006

Angiotech to appeal judgement regarding UK patent

Angiotech Pharmaceuticals has announced that it intends to appeal a UK trial court decision to revoke Angiotech's UK designation of its European Patent No. 0,706,376.

24 Feb 2006